Array BioPharma Inc. (NASDAQ:ARRY) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters To a Vote of Security Holders

On October26, 2017, Array BioPharma Inc. (the “Company”) held its Annual Meeting. There were 137,196,593 shares of common stock represented in person or by valid proxies at the Annual Meeting and entitled to be voted, representing 79.9% of the 171,766,223 shares of common stock outstanding as of the August30, 2017 record date. The stockholders voted on four proposals at the Annual Meeting. The proposals are described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission dated September13, 2017. The following is a tabulation of the final voting results for each of the proposals presented and voted on at the Annual Meeting.

Proposal 1: The Company’s stockholders elected three ClassII Directors, each to serve for a three-year term expiring at the 2020 annual meeting of stockholders and until their respective successors have been duly elected and qualified. The votes regarding this proposal were as follows:

Proposal 2: The Company’s stockholders approved the advisory vote on executive compensation. The votes regarding this proposal were as follows:

Proposal 3: The Company’s stockholders approved the holding an advisory vote of stockholders on executive compensation on an annual basis. The votes regarding this proposal were as follows:

Proposal 4: The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending June30, 2018. The votes regarding this proposal were as follows: